---
title: "Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Morgan Stanley"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285511464.md"
description: "Morgan Stanley analyst David Bailey has maintained a Buy rating on Resmed Inc CHESS Depositary Interests, with shares closing at A$28.78. The analyst consensus is Strong Buy, with a price target of A$43.13, indicating a potential upside of 49.86%. Bailey, a 4-star analyst, also previously set a price target of A$41.72 in a May report. He covers the Healthcare sector, focusing on companies like Ramsay Health Care and Telix Pharmaceuticals."
datetime: "2026-05-07T07:45:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285511464.md)
  - [en](https://longbridge.com/en/news/285511464.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285511464.md)
---

# Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Morgan Stanley

In a report released yesterday, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. The company’s shares closed today at A$28.78.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Bailey is a 4-star analyst with an average return of 10.0% and a 45.92% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, Telix Pharmaceuticals, and Cochlear .

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has an analyst consensus of Strong Buy, with a price target consensus of A$43.13, which is a 49.86% upside from current levels. In a report released on May 4, Morgans also maintained a Buy rating on the stock with a A$41.72 price target.

### Related Stocks

- [RMD.US](https://longbridge.com/en/quote/RMD.US.md)
- [RMD.AU](https://longbridge.com/en/quote/RMD.AU.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [RHC.AU](https://longbridge.com/en/quote/RHC.AU.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [COH.AU](https://longbridge.com/en/quote/COH.AU.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)
- [CHEOY.US](https://longbridge.com/en/quote/CHEOY.US.md)

## Related News & Research

- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)
- [ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status](https://longbridge.com/en/news/285006339.md)
- [Challenger  (CFIGF) Gets a Buy from Ord Minnett](https://longbridge.com/en/news/286831053.md)
- [Jefferies Sticks to Their Buy Rating for Home Consortium Ltd (HMC)](https://longbridge.com/en/news/286676723.md)
- [Shaw and Partners Reaffirms Their Buy Rating on Wisr Ltd. (WZR)](https://longbridge.com/en/news/286688085.md)